The Cystic Fibrosis Foundation has agreed to provide Prime Medicine Inc. an additional investment of up to $24 million to continue the development of a gene editing therapy for people with cystic fibrosis. Prime Medicine uses a gene editing technology called prime editing, which enables a wide range of modifications to the DNA with a high degree of precision.
Prime Medicine Inc. has announced its new preclinical program for the treatment of α1-antitrypsin deficiency (AATD). The program is advancing through its final stages of lead optimization, with an IND and/or clinical trial application (CTA) filing anticipated around the middle of next year.
Biopharma deals and M&A activity in 2024 continued to surge past the last two years, with deal value in the first three quarters jumping 14.5% year-over-year. The total climbed from $130.38 billion through 3Q23 to an impressive $149.24 billion so far in 2024, the highest value in the first nine months of a year, according to BioWorld’s records. Q3 alone saw $49.81 billion in deals, following a strong Q2 at $55.26 billion. Meanwhile, M&As skyrocketed 75.5% in 2024, hitting $98.02 billion, up from $55.82 billion during the first nine months of last year.
Biopharma deals and M&A activity in 2024 continued to surge past the last two years, with deal value in the first three quarters jumping 14.5% year-over-year. The total climbed from $130.38 billion through 3Q23 to an impressive $149.24 billion so far in 2024, the highest value in the first nine months of a year, according to BioWorld’s records. Q3 alone saw $49.81 billion in deals, following a strong Q2 at $55.26 billion. Meanwhile, M&As skyrocketed 75.5% in 2024, hitting $98.02 billion, up from $55.82 billion during the first nine months of last year.
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan to develop reagents for ex vivo T-cell therapies. While the programs and targets have yet to be disclosed, BMS is expanding its CAR T development, begun more than five years ago, with this deal.
Prime Medicine Inc. has announced its plans to strategically focus its efforts on a set of high value programs as it advances its pipeline of next-generation gene editing therapies.
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan to develop reagents for ex vivo T-cell therapies. While the programs and targets have yet to be disclosed, BMS is expanding its CAR T development, begun more than five years ago, with this deal.
Chronic granulomatous disease (CGD) is an immunodeficient disorder that is caused by mutations in genes that encode proteins of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzyme complex.
The FDA has cleared Prime Medicine Inc.’s IND application for PM-359 for the treatment of chronic granulomatous disease (CGD), enabling initiation of a phase I/II trial in the U.S.
The Cystic Fibrosis Foundation (CF Foundation) has agreed to provide Prime Medicine Inc. with up to $15 million to support the development of prime editors for the treatment of cystic fibrosis (CF).
